Navigation Links
Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
Date:2/13/2008

Mexico is the First Latin American Country to Approve Treatment

BASINGSTOKE, England and CAMBRIDGE, Massachusetts, February 13 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP)(NASDAQ: SHPGY)(TSX: SHQ), the global specialty biopharmaceutical company, announced that ELAPRASE(R) (idursulfase), a human enzyme replacement therapy for the treatment of Hunter syndrome, has been approved for commercial sale by the Mexican Federal Commission for the Protection against Sanitary Risk (COFEPRIS). Mexico is the tenth-largest pharmaceutical market in the world(1) and the first Latin American country to approve ELAPRASE.

Hunter syndrome, also known as Mucopolysaccharidosis II (MPS II), is a serious, life-threatening genetic condition mainly affecting males that results from an absence of, or deficiency in, the lysosomal enzyme iduronate-2-sulfatase. Without sufficient amounts of this enzyme, cellular waste products accumulate in tissues and organs, which then begin to malfunction, leading to severe clinical complications and early mortality.

ELAPRASE, developed by Shire Human Genetic Therapies (HGT), is the first and only enzyme replacement therapy approved for people suffering from Hunter syndrome. The medicine is given as a weekly infusion and is designed to replace the deficient iduronate-2-sulfatase enzyme.

"The approval of ELAPRASE in Mexico marks a significant milestone because for the first time, Hunter syndrome patients in Mexico have access to treatment," said Sylvie Gregoire, President of Shire HGT, the Shire business unit focused on genetic diseases. "This approval also underscores our dedication and commitment to provide meaningful treatments for patients suffering from serious and often neglected diseases around
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
2. Genzyme Receives Approval to Market Elaprase(R) in Japan
3. Clexane(R)/Lovenox(R) Approved in Japan
4. EVICEL(TM) Fibrin Sealant (Human) Approved for General Hemostasis in Surgery
5. Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer
6. Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
7. Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction
8. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
9. Biomoda Announces Collaborative Agreement With New Mexico Tech
10. Viramontes to Lead PPD Clinical Operations in Mexico, Central America and the Caribbean
11. Prestigious Bioethics Award for Scholar from Mexico
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... -- regulated information — Global biopharmaceutical company UCB, Inc. and ... launch of a new Pledge campaign for people with ... empowers the millions of Americans living with ... commitment to demand more: greater understanding of the condition, ... partial-onset seizure control.  More information is available at ...
(Date:6/18/2013)... June 18, 2013 The "Bioinformatics Market By ... Knowledge Management Tools & Data Analysis Services) & Application (Genomics, ... the Major Market Drivers, Restraints, and Opportunities in ... Asia-Pacific and Rest of World. ... 22 Figures 364 ...
(Date:6/18/2013)... Canada (PRWEB) June 18, 2013 ... oversight of pharmaceutical advertising and promotion, and review ... Viewers will learn how to apply these principles ... examples:, ,     The fundamentals on FDA ... and promotional labeling ,     Assessing traditional and ...
(Date:6/18/2013)... June 18, 2013   Lexicon Pharmaceuticals, Inc. ... company focused on discovering breakthrough treatments for human ... has joined the company as its vice president ... brings extensive commercial experience to Lexicon, including both ... of therapeutic areas. Mr. Northcott has ...
Breaking Biology Technology:Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 2Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 3Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 4Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 5Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 6Bioinformatics Market Worth $7.5 Billion by 2017 2Bioinformatics Market Worth $7.5 Billion by 2017 3Drug Advertising and Promotion Labeling: FDA Regulations, New Webinar Hosted by Xtalks 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 3
... Golub Capital today announced that it,has provided a GOLD ... by MTS Health Investors, LLC (MTS). GOLD financings are,proprietary ... not disclosed., DDC, based in Fairfield, Ohio, is ... worldwide and the market leader in human DNA,identification testing ...
... quarter 2007 to $201 million, SAN DIEGO, Oct. ... reported financial results for the quarter ended,September 30, 2008. ... third quarter, including net product sales of $201.4 million, ... loss for the quarter ended,September 30, 2008 was $77.7 ...
... SAN JOSE, Calif., Oct. 21 Canary Foundation, a,nonprofit ... its Scientific Program Director, Dr. Sanjiv Sam Gambhir, has,been ... Academies Institute of,Medicine (IOM). This is one of the ... IOM, established in 1970 by the National Academy of,Sciences, ...
Cached Biology Technology:Golub Capital Provides Debt Financing to Support the Acquisition of DNA Diagnostics Center, Inc. by MTS Health Investors, LLC 2Amylin Pharmaceuticals Reports Third Quarter Financial Results 2Amylin Pharmaceuticals Reports Third Quarter Financial Results 3Amylin Pharmaceuticals Reports Third Quarter Financial Results 4Amylin Pharmaceuticals Reports Third Quarter Financial Results 5Amylin Pharmaceuticals Reports Third Quarter Financial Results 6Amylin Pharmaceuticals Reports Third Quarter Financial Results 7Amylin Pharmaceuticals Reports Third Quarter Financial Results 8Canary Foundation's Dr. Sanjiv Sam Gambhir Elected to the National Academies Institute of Medicine 2
(Date:6/18/2013)... a very large "dead zone" in the Gulf of ... the Chesapeake Bay this year, based on several NOAA-supported ... Michigan, Louisiana State University, and the Louisiana Universities ... Mexico hypoxic "dead" zone will be between 7,286 and ... ten largest recorded. That would range from an area ...
(Date:6/18/2013)... Health has awarded $12.7 million to match nine ... industry compounds to explore new treatments for patients ... muscular dystrophy and schizophrenia. The collaborative pilot initiative, ... is led by the National Center for Advancing ... Common Fund. , The process of developing a ...
(Date:6/18/2013)... 2013: The Association for Molecular Pathology is proud to ... for Experimental Biology (FASEB) on July 1, 2013. The ... 3, 2013. , The 26 constituent societies of ... common vision for the advancement of research and education ... research is more important now than ever," said Jennifer ...
Breaking Biology News(10 mins):NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 2NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 3NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 4NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4
... ease symptoms in people with Parkinson's disease and other ... electrical signals of their diseased brains. , Despite the ... by the Food and Drug Administration and can be ... mechanisms by which deep brain stimulation alleviates disease symptoms ...
... robotic vehicle designed for underwater exploration plunged repeatedly ... sinkhole in late May, finding its previously undiscovered ... a sonar map of its inner dimensions. The ... by Carnegie Mellon University’s Robotics Institute. , During ...
... simple notion of copying the body’s own natural "waste disposal" ... estimated 80 percent of patients with urea cycle disorders --- ... this week’s New England Journal of Medicine summarizing a quarter ... of sodium phenylacetate and sodium benzoate, two chemicals the body ...
Cached Biology News:How brain pacemakers erase diseased messages 2How brain pacemakers erase diseased messages 3NASA-funded robotic sub finds bottom of world's deepest sinkhole 2An 'elegant' idea proves its worth 25 years later 2
Sheep polyclonal to Melatonin ( Abpromise for all tested applications). Antigen: Melatonin Tg conjugate....
Goat polyclonal to DDDDK tag (FITC) ( Abpromise for all tested applications)....
...
DNA fragmentation factor & Inhibitor of CAD...
Biology Products: